Ocumension Therapeutics announced that the Group's application for initiating a phase III clinical trial in the People's Republic of China for OT-502 (DEXYCU®), one of the Group's key drug candidates, has recently been accepted by the Center for Drug Evaluation of the National Medical Products Administration of the PRC. DEXYCU®, approved to launch in the United States by the U.S. Food and Drug Administration on February 9, 2018, is the first and only FDA-approved, sustained-release intraocular drug for the treatment of postoperative inflammation indication. Inflammation is a common symptom following cataract surgery and may cause severe complications if not treated timely. To date, hormonal and antibiotic eye drops are common in clinical use to treat postoperative inflammation over two to four weeks. However, cataract surgery patients are often elderly, and their medication compliance is worse. Utilizing the drug delivery platform Verisome®, OT-502 (DEXYCU®) can deliver dexamethasone into anterior chamber, directly inhibiting the synthesis and release of inflammatory mediators in anterior chamber. It works good in inhibiting responses to postoperative anterior chamber inflammation and avoids frequent use of topical hormonal eye drops, which effectively resolves non-compliance of cataract surgery patients, so as to provide a better treatment choice for the management of postoperative inflammation.